Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients

Adipocyte fatty acid binding protein (A-FABP) has been reported to be involved in insulin resistance, lipid metabolism, and atherosclerosis; however, little is known about the effect of medication on the change in circulating A-FABP in human subjects. We evaluated the effects of angiotensin II type...

Full description

Saved in:
Bibliographic Details
Published in:Heart and vessels 2011-07, Vol.26 (4), p.408-413
Main Authors: Miyoshi, Toru, Doi, Masayuki, Hirohata, Satoshi, Kamikawa, Shigeshi, Usui, Shinichi, Ogawa, Hiroko, Sakane, Kosuke, Izumi, Reishi, Ninomiya, Yoshifumi, Kusachi, Shozo
Format: Article
Language:English
Subjects:
Aged
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Ankle Brachial Index
Antagonist drugs
Antihypertensive Agents - therapeutic use
Arteries - drug effects
Arteries - physiopathology
Atherosclerosis
Biomarkers - blood
Biomedical Engineering and Bioengineering
Blood Pressure - drug effects
C-Reactive Protein - metabolism
Cardiac Surgery
Cardiology
Cellular biology
Clinical outcomes
Down-Regulation
Drug therapy
Elasticity
Fatty Acid-Binding Proteins - blood
Fatty acids
Female
Humans
Hypertension
Hypertension - blood
Hypertension - drug therapy
Hypertension - physiopathology
Imidazoles - therapeutic use
Japan
Linear Models
Male
Medicine
Medicine & Public Health
Middle Aged
Original Article
Prospective Studies
Proteins
Tetrazoles - therapeutic use
Time Factors
Treatment Outcome
Vascular Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adipocyte fatty acid binding protein (A-FABP) has been reported to be involved in insulin resistance, lipid metabolism, and atherosclerosis; however, little is known about the effect of medication on the change in circulating A-FABP in human subjects. We evaluated the effects of angiotensin II type 1 receptor blocker (ARB) on arterial stiffness and its association with serum A-FABP in patients with hypertension. Thirty patients newly diagnosed with essential hypertension were treated with olmesartan (20 mg/day), an ARB, for 6 months. Serum levels of A-FABP and high-sensitivity C-reactive protein (hsCRP) were examined and the cardio-ankle vascular index (CAVI), which is a marker of arterial stiffness, was also determined. Serum A-FABP at baseline was significantly correlated with the body mass index ( r  = 0.45, P  = 0.01), homeostasis model assessment as a marker of insulin resistance ( r  = 0.53, P  
ISSN:0910-8327
1615-2573
DOI:10.1007/s00380-010-0060-x